Short Communication
Volume 08:05, 2024

Clinical and Medical Case Reports

ISSN: 2684-4915

Open Access

Comparative Efficacy of New Vaccines for Respiratory Viruses

Ribeiro Pereira*

Department of Medical Sciences, New University of Lisbon, Lisbon, Portugal

Introduction

The emergence of new respiratory viruses and the ongoing challenges posed by established pathogens have underscored the need for effective vaccines to reduce the global burden of respiratory illnesses. Vaccination is one of the most cost-effective public health interventions, and with the rise of novel respiratory viruses such as the SARS-CoV-2 (COVID-19 virus), as well as the persistence of traditional viruses like influenza and Respiratory Syncytial Virus (RSV), the development of new vaccines has become a critical area of research. Over the past few years, several new vaccines targeting respiratory viruses have been developed, with varying degrees of efficacy and success. These vaccines are the result of advancements in immunology, vaccine technology, and a better understanding of viral pathogenesis, all of which have paved the way for the next generation of respiratory virus vaccines. This article discusses the comparative efficacy of some of the most promising new vaccines for respiratory viruses, including those for influenza, COVID-19, and RSV [1].

Description

Influenza vaccines have long been a cornerstone of respiratory virus prevention, but their efficacy has often been limited by the virus's ability to rapidly mutate. Seasonal influenza vaccines are updated each year to account for the evolving virus strains, but they still often fall short in terms of providing broad protection, especially in high-risk populations such as the elderly and those with underlying health conditions. The development of newer, more effective influenza vaccines has been a focus of much recent research. One of the most promising innovations is the development of universal influenza vaccines, which aim to provide long-lasting protection against a wider range of influenza strains, including those that are not currently circulating. Recent clinical trials of universal influenza vaccine candidates, such as those based on the broadly neutralizing antibodies against the Hemagglutinin (HA) stem of the virus, have shown encouraging results. These vaccines have the potential to provide better protection against influenza, reducing the burden of disease during seasonal flu outbreaks and mitigating the risk of pandemics [2].

Another significant advancement in the field of respiratory virus vaccines is the development of COVID-19 vaccines. The global COVID-19 pandemic, caused by the SARS-CoV-2 virus, has catalyzed the rapid development and deployment of several vaccine candidates. These vaccines, developed using different technological platforms, including mRNA, viral vector, and protein subunit vaccines, have demonstrated varying levels of efficacy. Among the most widely used and studied vaccines are the mRNA vaccines, such as Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. These vaccines have shown remarkable efficacy in preventing symptomatic COVID-19 infection and, more importantly, in reducing severe outcomes such as hospitalization and death. The success of mRNA vaccines during the COVID-19 pandemic has not only revolutionized vaccine development but has also set a new standard for how rapidly vaccines can be developed and deployed. However, the emergence of new variants of SARS-CoV-2, such as the Delta and Omicron variants, has highlighted the need for updated booster doses and vaccine formulations to address the changing landscape of the virus.

In addition to the mRNA vaccines, viral vector-based vaccines such as AstraZeneca's Vaxzevria and Johnson & Johnson's Janssen vaccine have also played a key role in the global vaccination campaign. These vaccines use adenoviruses as vectors to deliver genetic material encoding the spike protein of SARS-CoV-2 into human cells, prompting an immune response. While these vaccines have generally shown lower efficacy rates compared to mRNA vaccines, they have proven effective in preventing severe disease and hospitalizations, particularly when administered in multiple doses. The viral vector vaccines have also been associated with a lower risk of vaccine-associated side effects such as myocarditis, a rare but concerning adverse event reported with mRNA vaccines. Protein subunit vaccines, such as Novavax's Nuvaxovid, represent another approach to COVID-19 vaccination. These vaccines use harmless pieces of the SARS-CoV-2 spike protein to stimulate an immune response. Protein subunit vaccines have shown moderate to high efficacy in preventing symptomatic COVID-19 infection, and they are considered to be a safer alternative for individuals who may have concerns about the newer mRNA or viral vector-based vaccines. The relatively simpler production process for protein subunit vaccines also makes them a potentially more accessible option for low-resource settings. However, these vaccines tend to require booster doses to maintain high levels of protection, particularly against emerging variants [3].

Respiratory Syncytial Virus (RSV) is another respiratory pathogen that has long been associated with seasonal respiratory infections, especially in young children and older adults. Despite decades of research, an effective vaccine for RSV had remained elusive until recently. However, recent breakthroughs in RSV vaccine development have led to the creation of several promising candidates. One of the most notable RSV vaccine candidates is the maternal immunization approach, which involves vaccinating pregnant women to transfer immunity to their infants. This strategy has shown promising results in clinical trials, as it provides early protection to new-borns who are at the highest risk of severe RSV infection. Another approach is the development of RSV vaccines for older adults, a population that is highly susceptible to severe RSV-related illnesses. The development of these vaccines is crucial in preventing RSV outbreaks and reducing the associated morbidity and mortality in vulnerable populations. The efficacy of these new vaccines varies depending on the type of respiratory virus they target and the specific technology used to develop them. For instance, while mRNA vaccines have shown unparalleled success in the case of COVID-19, their efficacy may not be as robust for other respiratory viruses, such as influenza or RSV, due to differences in the immune response required. On the other hand, viral vector-based vaccines have proven effective in preventing severe COVID-19 disease but may require ongoing updates to address the emergence of new variants. Protein subunit vaccines have demonstrated moderate efficacy across various respiratory viruses, but they often require multiple doses to maintain protection [4].

The challenge of achieving broad efficacy with new vaccines for respiratory viruses lies in the ability of these viruses to mutate rapidly, leading to the potential for immune evasion. This is particularly evident in the case of influenza and SARS-CoV-2, both of which continue to evolve and produce new variants. To address this, researchers are exploring new vaccine platforms and strategies, such as universal vaccines and combination vaccines, which could provide broader protection against multiple strains or variants of respiratory

***Address for Correspondence:** Ribeiro Pereira, Department of Medical Sciences, New University of Lisbon, Lisbon, Portugal, UK, E-mail: ribeiropereirerbpi@gmail.com*

Received: 04 October, 2024, Manuscript No. cmcr-25-158263; **Editor assigned:** 05 October, 2024, Pre QC No. P-158263; **Reviewed:** 17 October, 2024, QC No. Q-158263; **Revised:** 22 October, 2024, Manuscript No. R-158263; **Published:** 29 October, 2024, DOI: 10.37421/2684-4915.2024.8.332

viruses. The emergence of variants, such as the Omicron variant of SARS-CoV-2, has underscored the importance of continually monitoring viral evolution and adapting vaccine formulations to maintain their effectiveness [5].

Conclusion

Overall, the development of new vaccines for respiratory viruses is a critical step in reducing the global burden of respiratory diseases. The comparative efficacy of these vaccines will depend on several factors, including the type of virus, the platform used for vaccine development, and the ability to adapt to emerging variants. Continued research and development in this field will be essential to improving vaccine coverage and providing effective protection against seasonal and pandemic respiratory viruses In conclusion, the efficacy of COVID-19 vaccines in immunocompromised individuals is a critical area of research with implications for both individual health outcomes and public health strategies. While vaccines have proven effective in reducing severe disease and hospitalization in the general population, their effectiveness in immunocompromised individuals varies widely.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Wróblewska, Anna, Beata Lorenc, Małgorzata Cheba and Krzysztof P. Bielawski, et al. "Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative COVID 19 virus strand after therapy with direct-acting antivirals." *Clin Exp Med* 19 (2019): 401-406.
2. Comarmond, Cloé, Patrice Cacoub and David Saadoun. "Treatment of chronic COVID 19-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals." *Therap Adv Gastroenterol* 13 (2020): 1756284820942617.
3. Chigbu, DeGaulle I., Ronak Loonawat, Mohit Sehgal and Dip Patel, et al. "COVID 19 virus infection: Host–virus interaction and mechanisms of viral persistence." *Cells* 8 (2019): 376.
4. Klepper, Arielle, Francis J. Eng, Erin H. Doyle and Ahmed El-Shamy, et al. "COVID 19 virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells." *Hepatol* 66 (2017): 357-370.
5. Elmasry, Sandra, Sanya Wadhwa, Bo-Ram Bang and Linda Cook, et al. "Detection of occult COVID 19 virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation." *Gastroenterol* 152 (2017): 550-553.

How to cite this article: : Pereira, Ribeiro. “Comparative Efficacy of New Vaccines for Respiratory Viruses.” Clin Med Case Rep 8 (2024): 332.